

Title (en)
NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 101P3A11 OR PHOR-1 USEFUL IN TREATMENT AND DETECTION OF CANCER

Title (de)
ZUR BEHANDLUNG UND ZUM NACHWEIS VON KREBS GEEIGNETE NUKLEINSÄUREN UND ENTSPRECHENDE PROTEINE MIT DER BEZEICHNUNG 101P3A11 ODER PHOR-1

Title (fr)
ACIDES NUCLEIQUES ET PROTEINES CORRESPONDANTES DITS 101P3A11 OU PHOR-1 SERVANT AU TRAITEMENT ET A LA DETECTION DE CANCERS

Publication
EP 1539805 A4 20051116 (EN)

Application
EP 02736898 A 20020515

Priority

- US 0215520 W 20020515
- US 29111801 P 20010515
- US 146901 A 20011031
- US 1706601 A 20011214

Abstract (en)
[origin: WO02092842A2] A novel gene (designated 101P3A11 or PHOR-1) and its encoded, and variants thereof, are described wherein 101P3A11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein, or variants thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 101P3A11 can be used in active or passive immunization.

IPC 1-7
C07K 14/00; **C07K 16/00**; **C07H 21/02**; **A61K 39/395**; **A61K 38/00**; **A61K 48/00**; **C12Q 1/68**; **G01N 33/53**

IPC 8 full level
A01K 67/027 (2006.01); **A61K 38/00** (2006.01); **A61K 39/395** (2006.01); **A61K 48/00** (2006.01); **A61P 35/00** (2006.01); **C07K 14/47** (2006.01); **C07K 16/18** (2006.01); **C07K 16/28** (2006.01); **C07K 16/46** (2006.01); **C12N 5/07** (2010.01); **C12N 5/0783** (2010.01); **C12N 5/09** (2010.01); **C12N 5/10** (2006.01); **C12N 15/09** (2006.01); **C12P 21/08** (2006.01); **C12Q 1/68** (2006.01)

CPC (source: EP)
A61P 35/00 (2017.12); **C07K 14/47** (2013.01); **C07K 16/28** (2013.01); **A61K 2039/505** (2013.01); **C07K 2317/34** (2013.01)

Citation (search report)

- [PX] WO 0173032 A2 20011004 - CORIXA CORP [US], et al
- [PX] WO 0174904 A2 20011011 - CURAGEN CORP [US], et al
- [T] WO 03009814 A2 20030206 - MILLENNIUM PHARM INC [US], et al & DATABASE EMBL 6 February 2003 (2003-02-06), "Prostate cancer marker protein", XP002345926, retrieved from EBI Database accession no. ADB75619
- See references of WO 02092842A2

Citation (examination)

- WO 9733602 A1 19970918 - CYTEL CORP [US]
- WO 0125434 A1 20010412 - UROGENESYS INC [US]
- WO 0044775 A2 20000803 - EPIMMUNE INC [US], et al

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)
WO 02092842 A2 20021121; **WO 02092842 A3 20050421**; AU 2002309873 B2 20071018; AU 2008200363 A1 20080221; AU 2008200363 A8 20080313; AU 2008200363 B2 20100812; CA 2447564 A1 20021121; EP 1539805 A2 20050615; EP 1539805 A4 20051116; IL 158860 A0 20040512; JP 2005512509 A 20050512

DOCDB simple family (application)
US 0215520 W 20020515; AU 2002309873 A 20020515; AU 2008200363 A 20080118; CA 2447564 A 20020515; EP 02736898 A 20020515; IL 15886002 A 20020515; JP 2002589708 A 20020515